Skip to main content
SpringerLink
Log in

Tiotropium Bromide

A Review of its Use as Maintenance Therapy in Patients with COPD

  • Adis Drug Evaluation
  • Published:
Treatments in Respiratory Medicine

Abstract

Abstract

Tiotropium bromide (Spiriva®) is a long-acting anticholinergic bronchodilator that maintains bronchodilation for at least 24 hours, allowing once-daily administration. The active moiety is the tiotropium cation (tiotropium); tiotropium bromide 22.5µg is equivalent to 18µg of tiotropium cation.

Greater improvements in lung function from baseline (primary endpoint mean trough FEV1) were observed with inhaled tiotropium 18µg once daily than with placebo in 6-month and 1-year randomized, double-blind trials in patients with COPD. Tiotropium improved lung function (trough FEV1 response) more effectively than ipratropium bromide (ipratropium) 40µg four times daily in 1-year clinical trials, and was at least as effective as salmeterol 50µg 12-hourly in 6-month trials. Preliminary data suggest that tiotropium alone or in combination with once-daily formoterol has a greater bronchodilator effect than twice-daily formoterol in patients with COPD.

Improvements in patients’ perception of health-related quality of life (HR-QOL) or dyspnea were greater with tiotropium than with placebo or ipratropium, and were similar to those with salmeterol. Reductions in the frequency and severity of acute exacerbations and in the use of rescue medication were also greater with tiotropium than with ipratropium or placebo. There was no evidence of tachyphylaxis with tiotropium during 1-year clinical trials.

Inhaled tiotropium was generally well tolerated in clinical trials. Apart from dry mouth, the type and incidence of adverse events with tiotropium were similar to those with ipratropium, salmeterol or placebo in patients with COPD.

In conclusion, inhaled tiotropium 18µg once daily improved lung function, dyspnea, and HR-QOL, and decreased the incidence of acute COPD exacerbations and the use of rescue medication relative to placebo or ipratropium in clinical trials in patients with COPD. Tiotropium was at least as effective as salmeterol in terms of bronchodilator efficacy and improvements in dyspnea or HR-QOL. With the exception of dry mouth, the tolerability profile of tiotropium was similar to that with placebo, ipratropium, or salmeterol. Consequently, inhaled tiotropium is likely to be a valuable option for first-line, long-term maintenance therapy in the management of bronchoconstriction in patients with symptomatic COPD.

Pharmacodynamic Profile

Tiotropium bromide has a quaternary ammonium structure and acts as an anticholinergic bronchodilator; the active moiety is the tiotropium cation (tiotropium). A 22.5µg dose of tiotropium bromide provides 18µg of tiotropium. Orally inhaled tiotropium bromide antagonizes the muscarinic M1, M2, and M3 receptors located in airway smooth muscle, reversing vagally mediated bronchoconstriction.

Receptor binding assays and in vitro tests indicate that tiotropium bromide is kinetically selective for M1 and M3 receptors over the M2 receptor, unlike ipratropium bromide, which is nonselective. Animal and in vitro studies showed that tiotropium bromide was more potent (≈20-fold) than ipratropium bromide in displacing [3H]N-methylscopolamine (NMS) from muscarinic receptors, and had a more sustained protective effect (>70% inhibition) against NMS binding. Tiotropium bromide was a more potent inhibitor of bronchial contraction than atropine (≈ 23-fold), and had a slower onset and markedly longer duration of action than atropine or an equipotent dose of ipratropium bromide. Aerosol particle penetration is improved with tiotropium, without delaying mucus clearance from the lungs.

Tiotropium 4.5–36µg once daily for 4 weeks increased mean trough and average FEV1 and FVC and mean PEFR values from baseline compared with placebo, with no evidence of tachyphylaxis. Improvements in trough FEV1 from baseline with tiotropium 4.5–36µg were not dose dependent. Based on a lack of dose response, the optimal once-daily tiotropium dosage is 18µg. Steady-state trough FEV1 values are achieved within 48 hours of commencing tiotropium.

Sustained bronchodilation (for ≥24 hours) and an attenuation of the nocturnal decline in FEV1 that were unaffected by timing of the daily tiotropium dose were seen in randomized, double-blind, placebo-controlled studies in patients with stable COPD. The drug improved static and dynamic lung hyperinflation (evidenced by reduced trapped air volume and increased tidal volume and end-of-exercise inspiratory capacity), and improved exertional dyspnea (during activities of daily living and exertion) and exercise tolerance compared with placebo in randomized, double-blind studies.

In patients with stable COPD, improved sleep-related oxygen desaturation that was unaffected by the timing of the daily dose was seen with tiotropium but not with placebo. Clinically significant treatment-related disorders of conduction or rhythm, or changes in heart rate were not observed with tiotropium in this patient group.

Pharmacokinetic Profile

Mean maximal plasma concentrations (Cmax) were observed within 5 minutes of inhalation of a single dose of tiotropium 18µg in patients with COPD. Plasma drug levels declined to minimum concentrations (Cmin) within 1 hour of treatment in healthy volunteers. Mean steady-state Cmax concentrations (16 ng/L) were achieved after 2–3 weeks of once-daily inhaled tiotropium 18µg in elderly patients with COPD; tiotropium does not appear to accumulate once steady-state has been achieved.

The estimated absolute bioavailability of tiotropium at steady state in healthy volunteers was approximately 20–25%, and approximately 72% of the drug is bound to plasma proteins.

Excretion of tiotropium is predominantly renal (through active secretion by the kidneys), although in vitro studies suggest that cytochrome P450 (CYP) oxidation (possibly involving CYP2D6 and CYP3A4 enzymes) may have a minor role. In patients with COPD, renal excretion of the unchanged drug at 24 hours (Ae24) was approximately 7%. The mean plasma elimination half-life after single or multiple doses in healthy volunteers and elderly patients with COPD was approximately 5–6 days. The renal clearance and urinary excretion of tiotropium decrease with increasing age; however, these changes are not considered to be clinically significant.

Because of altered steady-state Cmax, Cmin, area under the concentration-time curve, and Ae24 values, caution is required with tiotropium administration in patients with moderate-to-severe renal impairment. The pharmacokinetics of tiotropium in patients with severe renal or hepatic impairment have not been studied.

Tiotropium does not interact with drugs such as cimetidine or ranitidine, which are also eliminated by active renal secretion.

Clinical Efficacy

Orally inhaled tiotropium bromide has been evaluated as a bronchodilator for the management of patients with COPD in randomized, double-blind 6-month and 1-year trials, and in several shorter studies. In clinical trials, COPD was diagnosed according to the American Thoracic Society guidelines. The bronchodilator effect was expressed as the trough FEV1 response (the mean change in FEV1 from baseline measured 1 hour prior to and immediately before a scheduled dose), and was the primary endpoint in all but two clinical trials. The bronchodilator effect with tiotropium 18µg once daily was superior to that with placebo in several well designed trials in patients with COPD. Moreover, greater improvements in mean peak and average FEV1 responses occurred with tiotropium but not with placebo. Mean trough, peak, and average FVC responses, and weekly mean morning and evening PEFR values were also improved to a greater extent with tiotropium than with placebo.

Tiotropium demonstrated a greater bronchodilator effect than ipratropium bromide (hereafter referred to as ipratropium when used at approved dosages) 40µg four times daily in two 1-year trials in patients with COPD. Mean peak and average FEV1, mean trough FVC responses, and weekly mean morning and evening PEFR values were also increased to a greater extent with tiotropium than with ipratropium.

In one of the two 6-month trials that compared the efficacy of tiotropium with that of inhaled salmeterol 50µg twice daily, greater improvements from baseline in mean trough, peak, and average FEV1 and FVC responses were seen with tiotropium than with salmeterol. Increases in weekly mean evening, but not morning, PEFR values were generally greater with tiotropium than salmeterol. In the second trial, improvement in the primary endpoint (mean trough FEV1 response from baseline) with tiotropium or salmeterol was similar, although peak and average responses were superior with tiotropium.

Preliminary results from a 6-week crossover study in patients with COPD suggested that tiotropium alone or in combination with once-daily formoterol improved mean trough and average FEV1 and trough FVC values from baseline to a greater extent than twice-daily formoterol.

More patients achieved a clinically important improvement (increase of ≥1 unit) in the transitional dyspnea index focal score (a measure of dyspnea-related impairment) with tiotropium than with placebo in the 1-year trials. Tiotropium was superior to ipratropium in 1-year trials, and was at least as effective as salmeterol in 6-month trials, in achieving a clinically important improvement in focal scores.

Tiotropium recipients experienced fewer COPD exacerbations than placebo or ipratropium recipients and had fewer and shorter COPD-related hospitalizations compared with placebo recipients. Unlike salmeterol, tiotropium lengthened the time to onset of the first exacerbation and decreased the number of exacerbations compared with placebo in two 6-month trials. Similar proportions of tiotropium, salmeterol, and placebo recipients required COPD-related hospitalizations.

According to the St George’s Respiratory Questionnaire, more patients achieved a clinically meaningful improvement (a reduction of ≥4 units from baseline) in heath-related quality of life with tiotropium than with placebo, ipratropium, or salmeterol in 6-month or 1-year trials. Results from the Short Form 36 questionnaire confirmed that greater improvements in physical domains occurred with tiotropium than with placebo or ipratropium. The need for rescue treatment with albuterol (salbutamol) was reduced with tiotropium compared with placebo or ipratropium, but was similar to that with salmeterol.

The increased cost of treatment with tiotropium over 1 year compared with ipratropium in patients with COPD was €180 per patient per year. The higher acquisition cost of tiotropium was partially offset by reduced healthcare utilization costs.

Tolerability

Inhaled tiotropium was generally well tolerated in all clinical trials. Similar percentages of tiotropium, ipratropium, salmeterol, or placebo recipients reported at least one adverse event in studies of up to 1 year. Apart from dry mouth, tiotropium appears to have a similar tolerability profile to that of placebo, ipratropium, or salmeterol. Dry mouth (an event likely to be related to the pharmacologic activity of tiotropium) occurred more frequently with tiotropium than with placebo (6-fold increase; p < 0.05), ipratropium (2-fold increase; p = 0.03) or salmeterol (4-fold increase; p-value not reported). Dry mouth, constipation, and urinary tract infections were reported more frequently with increasing age with tiotropium than with ipratropium in 1-year trials.

Similar percentages of tiotropium, ipratropium, or placebo recipients experienced serious adverse events or adverse events leading to withdrawal in the 1-year trials. However, significantly (p < 0.01) fewer tiotropium than salmeterol or placebo recipients withdrew because of adverse events in the 6-month trials.

Tiotropium was not associated with any clinically significant changes in ECG recordings, vital signs or laboratory values in 6-month and 1-year trials. Heart rate or rhythm disorders were uncommon with tiotropium (4%), placebo (2%) or ipratropium (5%) in 1-year trials.

Dosage and Administration

Inhaled tiotropium bromide is a bronchodilator indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD. It is approved in >40 countries worldwide, including the US and those in the EU. The recommended dosage is a once-daily inhalation of tiotropium 18µg via a dry powder capsule inhaler, the HandiHaler®, at the same time each day. Tiotropium should not be used as an initial treatment for episodes of acute bronchospasm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Table III
Fig. 3
Fig. 4
Fig. 5
Table IV

Similar content being viewed by others

Notes

  1. 1 The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction: a clinicopathological study of patients in London and Chicago. Lancet 1966 Apr 16; 1(7442): 830–5

    Article  PubMed  CAS  Google Scholar 

  2. National Institutes of Health: National Heart Lung and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2003. Executive summary [online]. Available from URL: http://www.goldcopd.com [Accessed 2003 Aug 20]

  3. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004 Jun 24; 350(26): 2645–53

    Article  PubMed  CAS  Google Scholar 

  4. Sutherland ER, Cherniak RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004 Jun 24; 350(26): 2689–97

    Article  PubMed  CAS  Google Scholar 

  5. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52(5–6): 521–7

    Article  PubMed  CAS  Google Scholar 

  6. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996 Dec; 48(4): 531–65

    PubMed  CAS  Google Scholar 

  7. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000 Feb; 117 (2 Suppl.): 63S–6S

    Article  PubMed  CAS  Google Scholar 

  8. Van Noord JA. Tiotropium bromide: a viewpoint by JA van Noord. Drugs 2002; 62(8): 1204–5

    Article  Google Scholar 

  9. Haddad EB, Mak JCW, Barnes J. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994 May; 45: 899–907

    PubMed  CAS  Google Scholar 

  10. Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002; 62(8): 1195–203

    Article  PubMed  CAS  Google Scholar 

  11. Disse B, Reichl R, Speck G, et al. BA 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993; 52(5–6): 537–44

    Article  PubMed  CAS  Google Scholar 

  12. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994 Dec; 150 (6 Pt 1): 1640–5

    PubMed  CAS  Google Scholar 

  13. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995 Sep; 8(9): 1506–13

    PubMed  CAS  Google Scholar 

  14. Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003 Oct; 58(10): 855–60

    Article  PubMed  CAS  Google Scholar 

  15. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with oncedaily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 Apr; 161 (4 Pt 1): 1136–42

    PubMed  CAS  Google Scholar 

  16. O’Donnell DE, Magnussen H, Aguilaniu B, et al. Spiriva (tiotropium) improves exercise tolerance in COPD [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A227

    Google Scholar 

  17. O’Donnell DE, Magnussen H, Aguilaniu B, et al. Spiriva (tiotropium) reduces exertional dyspnea in COPD [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A265

    Google Scholar 

  18. Magnussen H, O’Donnell DE, Casaburi R, et al. Spiriva® (tiotropium) reduces lung hyperinflation in COPD [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A227

    Google Scholar 

  19. van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002 Apr; 19(4): 639–44

    Article  PubMed  Google Scholar 

  20. McNicholas WT, Calverley PMA, Edwards C, et al. Effects of anticholinergic therapy (tiotropium) on REM-related desaturation (SaO2) and sleep quality in patients with COPD [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A280

    Google Scholar 

  21. O’Donnell DE, Magnussen H, Gerken F, et al. Mechanisms of improved exercise tolerance in COPD in response to tiotropium [abstract no. P1826]. Eur Respir J 2002 Sep; 20Suppl. 38: 288s

    Google Scholar 

  22. Langley S, Towse L, Kesten S, et al. Heart rate and rhythm analysis from Holter monitoring in COPD patients receiving tiotropium [abstract]. Am J Respir Crit Care Med 2002; 165 (8 Suppl. Pt 2): A592

    Google Scholar 

  23. Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004 May; 125(5): 1726–34

    Article  PubMed  CAS  Google Scholar 

  24. O’Donnell D, Marcinuik D, Hernandez P, et al. Spiriva (tiotropium) reduces lung hyperinflation at rest and during exercise [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169(7): A772

    Google Scholar 

  25. O’Donnell D, Maltais F, Sciurba F, et al. Spiriva (tiotropium) improves symptom-limited exercise tolerance in COPD patients [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169(7): A771

    Google Scholar 

  26. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise endurance with the combination of tiotropium and rehabilitative exercise training in COPD patients [abstract]. Am J Respir Crit Care Med 2004 Apr; 169(7): A756

    Google Scholar 

  27. Cooper B, Kukafka D, Casaburi R, et al. Tiotropium augments improvements in dyspnea and health-related quality of life following pulmonary rehabilitation in COPD patients [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169(7): A518

    Google Scholar 

  28. Briggs Jr D, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared to salmeterol in COPD patients [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169(7): A518

    Google Scholar 

  29. Food and Drug Administration. Clinical pharmacology and biopharmaceutics briefing document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3890Bl_06_Pharmacology-Biopharmaceutics.pdf [Accessed 2002 Sep 18]

  30. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 Feb; 19(2): 217–24

    Article  PubMed  CAS  Google Scholar 

  31. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. The Dutch/Belgian Tiotropium Study Group. Eur Respir J 2002 Feb; 19(2): 209–16

    Article  PubMed  CAS  Google Scholar 

  32. College Ter Beoordeling Van Geneesmiddelen Medicines Evaluation Board. Public assessment report: Spiriva 18µg, inhalation powder in hard capsules RVG 26191 [online]. Available from URL: http://www.cbg-meb.nl/nl/docs/gnsmiddl/par-spiriva.pdf [Accessed 2002 Jul 23]

  33. Donohue JF, Van Noord A, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002 Jul; 122(1): 47–55

    Article  PubMed  CAS  Google Scholar 

  34. Van Noord JA, Aumann J, Janssens E, et al. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract no. BO24]. 99th International Conference of the American Thoracic Society; 2003 May 16–21; Seattle, (WA), A320

  35. Huchon G, Verkindre C, Bart F, et al. Improvements with tiotropium on endurance measured by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients [abstract no. P1825]. Eur Respir J 2002; 20Suppl. 38: 287s

    Google Scholar 

  36. O’Donnell DE, Magnussen H, Gerken F, et al. Cardiovascular evaluation of tiotropium during constant-work rate exercise in COPD [abstract no. P430]. Eur Resp J 2003; 22Suppl. 45: 49s

    Google Scholar 

  37. Van Noord J, Aumann J, Jannsens E. Relation between acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPS patients [abstract no. 153]. Eur Resp J 2003 Sep; 22Suppl. 45: 4s

    Google Scholar 

  38. Celli BR, ZuWallack RL, Wang S, et al. Improvements in inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124(5): 1743–8

    Article  PubMed  Google Scholar 

  39. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984 Jun; 85(6): 751–8

    Article  PubMed  CAS  Google Scholar 

  40. Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD [abstract]. Am J Respir Crit Care Med 1999 Mar; 159 (3 Suppl. Pt 2): A524

    Google Scholar 

  41. Boehringer Ingelheim. Samenvatting van de productkenmerken [online]. Available from URL: http://www.cbg-meb.nl/IB-teksten/26191.PDF [Accessed 2002 Jul 24]

  42. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64(6–7): 457–64

    Article  PubMed  CAS  Google Scholar 

  43. Food and Drug Administration. Spiriva (tiotropium bromide inhalation powder) NDA 21-395 Boehringer Ingelheim Pharmaceuticals, Inc [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3890Bl_l_Boehringer%20Ingelheim.pdf [Accessed 2002 Sep 18]

  44. Tiirck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004; 44: 163–72

    Article  Google Scholar 

  45. Wanner A, ZuWallack R, Elias D, et al. Efficacy of once daily tiotropium (TIO) in stable COPD [abstract no. P3406]. 9th Annual Congress of the European Respiratory Society; 1999 Oct 9–13; Madrid, (abstracts-on-disk)

  46. San Pedro G, Elias DJ, Serby CW, et al. Tiotropium (Spiriva): one year bronchodilator efficacy established with once daily dosing in COPD patients [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3 Suppl. Pt 2): A749

    Google Scholar 

  47. Zu Wallack R, Jones PW, Kotch A, et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3 Suppl. Pt 2): A892

    Google Scholar 

  48. Mahler DA, Montner P, Brazinsky SA, et al. Tiotropium (Spiriva), a new long-acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3 Suppl. Pt 2): A892

    Google Scholar 

  49. Casaburi R, Briggs Jr DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000 Nov; 118(5): 1294–302

    Article  PubMed  CAS  Google Scholar 

  50. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003 May; 123(5): 1441–9

    Article  PubMed  CAS  Google Scholar 

  51. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003 Sep; 97(9): 1014–20

    Article  PubMed  CAS  Google Scholar 

  52. Briggs Jr DD, Witek TJ, Menjoge SS, et al. Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment [abstract no. P1589]. Eur Respir J 2002 Sep; 20Suppl. 38: 245s

    Google Scholar 

  53. Hodder RV, White RJ, Menjoge SS, et al. Effectiveness of tiotropium or salmeterol in COPD patients receiving inhaled steroids [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A228

    Google Scholar 

  54. Friedman M, Korducki L, Kesten S. Recovery of PEFR in COPD exacerbations in one year clinical trials [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Part 2): A270

    Google Scholar 

  55. Spencer S, Jones PW. Decline in health status over one year is eliminated by tiotropium. Tiotropium study group [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A228

    Google Scholar 

  56. Beeh KM, Beier J, Buhl R, et al. Efficacy of tiotropium in patients with mild to moderate COPD [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169(7): A519

    Google Scholar 

  57. Niewoehner D, Rice K, Cote C, et al. Reduced COPD exacerbations and associated health care utilization with once-daily tiotropium (TIO) in the VA medical system [abstract]. Am J Respir Crit Care Med 2004 Apr; 169(7): A207

    Google Scholar 

  58. Friedman M, Menjoge SS, Anton S, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004; 22(No. 11): 741–9

    Article  PubMed  Google Scholar 

  59. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003 May; 58(5): 399–404

    Article  PubMed  CAS  Google Scholar 

  60. Van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000 Apr; 55(4): 289–94

    Article  PubMed  Google Scholar 

  61. Vincken W, Greefhorst APM, Westbroek J, et al. Once-daily tiotropium (TIO) is more efficacious than Q.I.D. ipratropium (IB) as maintenance treatment of COPD [abstract no. P3407]. 9th Annual Congress of the European Respiratory Society; 1999 Oct 9–13; Madrid, (abstracts-on-disk)

  62. de Guia T, Punzal P, Canizares L, et al. Evaluation of the response of Filipino patients to tiotropium (EVEREST Study) [abstract]. Am J Respir Crit Care Med 2004 Apr; 169(7): A611

    Google Scholar 

  63. Food and Drug Administration. Clinical briefing document NDA 21-395 Spiriva (tiotropium bromide) inhalation powder for COPD [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3890Bl_05_Clinical%20Briefing-%20Part%201.pdf; http://www.fda.gov/ohrms/dockets/ac/02/briefing/3890Bl_05_Clinical%20Briefing-%20Part%202.pdf [Accessed 2002 Sep 18]

  64. Witek Jr TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003 Mar; 56(3): 248–55

    Article  PubMed  Google Scholar 

  65. Kesten S, Flanders S, Menjoge SS, et al. Improvements in COPD following treatment with tiotropium in elderly patients. Chest 2001 Oct; 120(4 Suppl.): 163S–4S

    Google Scholar 

  66. Weisman I, Menjoge SS, Serby CW, et al. Influence of gender on outcomes in large COPD clinical trials [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A281

    Google Scholar 

  67. American Thoracic Society. Standardisation of spirometry: 1994 update. Am J Respir Crit Care Med 1995 Sep; 152(3): 1107–36

    Google Scholar 

  68. Vincken WG, Vermiere P, Menjoge SS, et al. Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials [abstract]. Eur Respir J 2001 Sep; 18Suppl. 33: 331s

    Google Scholar 

  69. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med 1991; 85Suppl B: 25–31

    Article  PubMed  Google Scholar 

  70. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145(6): 1321–7

    PubMed  CAS  Google Scholar 

  71. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000 Feb; 117(2 Suppl.): 54S–7S

    Article  PubMed  CAS  Google Scholar 

  72. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992 Jun; 30(6): 473–83

    Article  PubMed  Google Scholar 

  73. Kesten S, Flanders J, Serby CW, et al. Compliance with tiotropium, a once daily dry powder inhaled bronchodilator, in one year COPD trials. Chest 2000 Oct; 118(4 Suppl.): 191S–2S

    Google Scholar 

  74. Oostenbrink JB, Rutten-van Mölken MPMH, Al J, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241–9

    Article  PubMed  CAS  Google Scholar 

  75. Boehringer Ingelheim International GmbH. Summary of product characteristics: Spiriva. Boehringer Ingelheim International GmbH, 2002

  76. Boehringer Ingelheim, Pfizer Inc. Prescribing information: Spiriva® Handihaler® (tiotropium bromide inhalation powder) [online]. Available from URL: http://www.spiriva.com [Accessed 2004 Mar 12]

  77. Boehringer Ingelheim, Pfizer Inc. FDA approves Spiriva Handihaler for the treatment of COPD [media release]. 2004

  78. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997 May; 349(9064): 1498–504

    Article  PubMed  CAS  Google Scholar 

  79. National Institutes of Health: National Heart Lung and Blood Institute. Morbidity and Mortality: 2002 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/02_chtbk.pdf [Accessed 2002 Aug 21]

  80. National Center for Health Statistics. Births, marriages, divorces, and deaths for 1997. Mon Vital Stat Rep 1998 Jul 28; 46(12): 1–18

    Google Scholar 

  81. National Heart Lung and Blood Institute. Data fact sheet: chronic obstructive pulmonary disease (COPD) [online]. Available from URL: http://www.nhlbi.nih.gov [Accessed 2002 Jul 15]

  82. Hoyert DL, Arias E, Smith BL, et al. Deaths: final data for 1999. Natl Vital Stat Rep 2001 Sep 21; 49(8): 1–113

    Google Scholar 

  83. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care [online]. Available from URL: http://www.nice.org.uk [Accessed 2004 Mar 16]

  84. Barnes PJ. Chronic obstructive pulmonary disease. N Eng J Med 2000 Jul 27; 343(4): 269–80

    Article  CAS  Google Scholar 

  85. Pauwels RA. National and international guidelines for COPD: the need for evidence. Chest 2000 Feb; 117(2 Suppl.): 20S–2S

    Article  PubMed  CAS  Google Scholar 

  86. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001 Apr; 10(4): 733–40

    Article  PubMed  CAS  Google Scholar 

  87. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 Aug; 23(8): 1296–310

    Article  PubMed  CAS  Google Scholar 

  88. Lipson DA. Redefining treatment in COPD: new directions in bronchodilator therapy. Treat Respir Med 2004; 3(2): 89–95

    Article  PubMed  CAS  Google Scholar 

  89. Redelmeier DA, Goldstein RS, Min ST, et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996 May; 109(5): 1163–8

    Article  PubMed  CAS  Google Scholar 

  90. Bauerle O, Chrusch CA, Younes M. Mechanisms by which COPD affects exercise tolerance. Am J Respir Crit Care Med 1998 Jan; 157(1): 57–68

    PubMed  CAS  Google Scholar 

  91. Mahler DA, Jones PW. Measurement of dyspnea and quality of life in advanced lung disease. Clin Chest Med 1997 Sep; 18(3): 457–69

    Article  PubMed  CAS  Google Scholar 

  92. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001; 18(6): 441–72

    Article  PubMed  CAS  Google Scholar 

  93. Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 2002; 1(4): 285–300

    Article  PubMed  CAS  Google Scholar 

  94. Boehringer Ingelheim, Pfizer Inc. Largest COPD outcomes study completes patient recruitment [media release]. 2004

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 770 Township Line Road, Suite 300, Yardley, Pennsylvania, 19067, USA

    Susan J. Keam & Gillian M. Keating

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Additional information

Data Selection

Sources: Medical literature published in any language since 1980 on tiotropium bromide, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘tiotropium bromide’ or ‘BA-679-BR’. EMBASE search terms were ‘tiotropium bromide’ or ‘BA-679’. AdisBase search terms were ‘tiotropium bromide’ or ‘BA 679’ or ‘BA 679 BR’. Searches were last updated 5 July 2004.

Selection: Studies in patients with COPD who received tiotropium bromide. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: COPD, tiotropium bromide, tiotropium, anticholinergic bronchodilators, pharmacodynamics, pharmacokinetics, therapeutic use, health-related quality of life, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keam, S.J., Keating, G.M. Tiotropium Bromide. Treat Respir Med 3, 247–268 (2004). https://doi.org/10.2165/00151829-200403040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200403040-00005

Keywords

Search

Navigation